Article Text

Download PDFPDF

Advanced chronic kidney disease among UK children
  1. Lucy Plumb1,2,
  2. Winnie Magadi1,
  3. Anna Casula1,
  4. Ben C Reynolds3,
  5. Mairead Convery4,
  6. Shuman Haq5,
  7. Shivaram Hegde6,
  8. Andrew Lunn7,
  9. Michal Malina8,9,
  10. Henry Morgan10,
  11. Mordi Muorah11,
  12. Kay Tyerman12,
  13. Manish D Sinha13,
  14. Dean Wallace14,
  15. Carol Inward15,
  16. Stephen Marks16,17,
  17. Dorothea Nitsch1,18,
  18. James Medcalf1,19
  1. 1 UK Renal Registry, UK Kidney Association, Bristol, UK
  2. 2 Population Health Sciences, University of Bristol Medical School, Bristol, UK
  3. 3 Department of Paediatric Nephrology, Royal Hospital for Children Glasgow, Glasgow, UK
  4. 4 Department of Paediatric Nephrology, Royal Belfast Hospital for Sick Children, Belfast, UK
  5. 5 Department of Paediatric Nephrology, Southampton Children's Hospital, Southampton, UK
  6. 6 Department of Paediatric Nephrology, University Hospital of Wales, Cardiff, UK
  7. 7 Department of Paediatric Nephrology, Nottingham University Hospitals NHS Trust, Nottingham, UK
  8. 8 National Renal Complement Therapeutics Centre, Great North Children's Hospital, Newcastle Upon Tyne, UK
  9. 9 Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
  10. 10 Department of Paediatric Nephrology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
  11. 11 Department of Paediatric Nephrology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
  12. 12 Department of Paediatric Nephrology, Leeds Children's Hospital, Leeds, UK
  13. 13 Department of Paediatric Nephrology, Evelina London Children's Hospital, London, UK
  14. 14 Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester, UK
  15. 15 Department of Paediatric Nephrology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
  16. 16 Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
  17. 17 NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, UK
  18. 18 Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
  19. 19 Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
  1. Correspondence to Dr Lucy Plumb, UK Renal Registry, Bristol, Bristol, UK; lucy.plumb{at}


The UK Renal Registry currently collects information on UK children with kidney failure requiring long-term kidney replacement therapy (KRT), which supports disease surveillance and auditing of care and outcomes; however, data are limited on children with chronic kidney disease (CKD) not on KRT.

Methods In March 2020, all UK Paediatric Nephrology centres submitted data on children aged <16 years with severely reduced kidney function as of December 2019, defined as an estimated glomerular filtration rate <30 mL/min/1.73 m2.

Results In total, 1031 children had severe CKD, the majority of whom (80.7%) were on KRT. The overall prevalence was 81.2 (95% CI 76.3 to 86.3) per million of the age-related population.

Conclusions The prevalence of severe CKD among UK children is largely due to a high proportion of children on long-term KRT. Expanding data capture to include children with CKD before reaching failure will provide greater understanding of the CKD burden in childhood.

  • Paediatrics
  • Nephrology
  • Epidemiology

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

What is already known on this topic

  • The UK Renal Registry routinely collects data on children with kidney failure receiving long-term kidney replacement therapies (KRT) such as dialysis or transplantation across the United Kingdom (UK), to support the audit and research of care and outcomes. Little is known about the prevalence of lesser stages of chronic kidney disease (CKD) not requiring KRT among UK children.

What this study adds

  • At the end of 2019, the prevalence of advanced CKD, defined as children aged under 16 years with an estimated glomerular filtration rate (eGFR) of <30ml/min/1.73m2, was 81.2 per million of the age-related population (pmarp). Most of this cohort were receiving long-term KRT (80.7%), specifically kidney transplantation, at the time of data collection. Separately, the prevalence of stages 4 (eGFR 15-29ml/min/1.73m2), stage 5 not on KRT (eGFR <15ml/min/1.73m2) and children requiring KRT was 9.5 (95% CI 7.9, 11.4), 6.2 (95% CI 4.9, 7.7), and 65.6 (95% CI 61.2, 70.2) pmarp, respectively.

How might this study affect research, practice, or policy

  • Collaboration between the UK Renal Registry and the British Association for Paediatric Nephrology has, for the first time, enabled description of children with advanced CKD on a national level. Continued data capture of children prior to reaching kidney failure will further our understanding of the epidemiology of CKD in UK children and their care and outcomes in childhood and beyond.


With chronic kidney disease (CKD) predicted to be one of the leading non-communicable causes of death worldwide by 2040,1 understanding the epidemiology of this condition is essential for planning health services. In children, much of our understanding is derived from a limited number of studies, which are often single centre or reflect a selected cohort of children with access to specialist care. It is unclear to what extent these estimates are generalisable.

The UK Renal Registry collects, analyses and reports data from UK nephrology centres on patients with kidney failure requiring long-term (>90 days) kidney replacement therapies (KRTs) such as dialysis or transplantation, to support audit and research of care and outcomes. This includes ‘static’ demographic (eg, sex, ethnicity) and clinical (eg, primary kidney disease diagnosis, date of KRT start) data, as well as ‘dynamic’ data, including blood pressure, haematological, biochemical and anthropometric measurements, which are received on a quarterly basis. Internationally, the UK Renal Registry is recognised as a robust, representative national dataset, benefitting from close collaboration with clinical and Information Technology leads at each of the 13 British Association for Paediatric Nephrology (BAPN) centres across the constituent nations to ensure complete data capture for affected children under their care. In recent years, data capture has expanded to include patients with lesser stages of CKD not on KRT, although currently these data are submitted by few centres. At the beginning of the COVID-19 pandemic, in response to concerns that children with advanced CKD would be at higher risk of serious infection, the UKRR, in conjunction with the BAPN, accelerated data capture of prevalent children across the UK primarily to support COVID-19 disease surveillance. We present findings from this initiative, which has enabled us to report the prevalence of advanced CKD among UK children, and to compare patient and clinical characteristics by KRT status.


In March 2020, the UKRR asked each of the 13 BAPN centres to report any children under the age of 18 years who, as of 31 December 2019, had an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m2, which is defined by the Kidney Disease Improving Global Outcomes consortium as ‘severely reduced’ function. As information is already routinely collected by the UKRR on children who receive long-term KRT, centres were asked to send information for patients not currently captured in the registry’s kidney failure dataset, including those with CKD stages 4 (eGFR 15–29 mL/min/1.73m2) and 5 (<15 mL/min/1.73 m2 not on KRT). Data including NHS number, date of birth, sex, ethnicity and primary kidney disease were collated; last height and serum creatinine values at the end of 2019 were requested for eGFR calculation using the updated Schwartz formula.2 Primary kidney disease was grouped using the 2012 European Renal Association-European Dialysis and Transplant Association Registry classification.3 Young people aged 16–18 years may be managed in either adult or paediatric nephrology settings; as a result, this report focused on the description and prevalence of children under 16 years with severely reduced kidney function for whom more complete capture of data was expected.


The UKRR received data from all 13 BAPN centres, totalling 385 patients. Based on height and creatinine data, 199 had an eGFR of less than 30 mL/min/1.73 m2 and were not on KRT. Twenty-seven children were excluded due to missing essential data, while the remainder (n=159) were excluded because they had a calculated eGFR of ≥30 mL/min/1.73 m2 or were reported as being on KRT. The UKRR kidney failure dataset identified 832 children prevalent to KRT at the same timepoint. Therefore, at the end of 2019, a total of 1031 children under 16 years of age were considered to have advanced CKD (table 1); using mid-year population estimates from the Office of National Statistics, this equated to a prevalence of 81.2 (95% CI 76.3 to 86.3) per million of the age-related population (pmarp): separately, the prevalence of stages 4, 5 (non-KRT) and failure requiring long-term KRT were 9.5 (95% CI 7.9 to 11.4), 6.2 (95% CI 4.9 to 7.7) and 65.6 (95% CI 61.2 to 70.2)pmarp, respectively. Children with stage 4 CKD accounted for most of the pre-KRT group (60.8%). Most children receiving KRT had a functioning kidney transplant (78.7%). Sex distributions were similar across both groups; children in the pre-KRT group were generally younger, with a median age of 9.8 (IQR 5.4–12.3) compared with 10.9 (IQR 7.4–13.8) years for the KRT cohort. A higher percentage of children of Asian, Black or ‘Other’ ethnicity was noted in the pre-KRT group. Overall, children with severely reduced kidney function were over-represented in poorer areas, with 27.8% living in the most deprived 20% of UK neighbourhoods, while 13.7% lived in the least deprived 20%. A higher proportion of glomerular disease was seen among children requiring long-term KRT, while congenital anomalies of the kidneys and urinary tract accounted for a higher percentage of the pre-KRT group.

Table 1

Demographic and clinical characteristics of UK children with advanced CKD, stratified by KRT status (n=1260)


This report describes the prevalence of severe stages of CKD (stages 4, 5 and on KRT) in UK children, which was achieved through UKRR-BAPN collaboration. Although data collection was driven by a public health need, this has enabled, for the first time, reporting of demographic and clinical features of children with stages 4 and 5 CKD not on long-term KRT on a national level. These findings highlight that most children with severely reduced kidney function have kidney failure which is managed with a kidney transplant. The relatively low prevalence of stage 5 (non-KRT) CKD suggests that most children who survive are treated with KRT.

At 81.2pmarp, the prevalence of severely reduced kidney function in UK children is generally higher than estimates from other nations.4 This may be partly explained by more comprehensive data capture and universal access to specialist care. A previous single-centre UK study estimated the prevalence of CKD (defined as an eGFR <60 mL/min/1.73 m2, excluding children with functioning kidney transplant) to be 90pmarp,5 although at least half of the cohort comprised of children with stage 3 CKD (eGFR 30–60 mL/min/1.73 m2), who were not included in this study. Based on stages 4, 5 and KRT (including transplant), we found a prevalence of 81.2pmarp; once milder stages are accounted for the prevalence may be higher. The overall high prevalence of severely reduced kidney function seen in this study is predominantly due to the high proportion of children on long-term KRT, which at 65.3pmarp is higher than most European estimates.6 The observation that higher proportions of children with advanced CKD lived in more deprived areas is concerning and warrants further investigation to determine whether this finding influences their kidney disease course and/or outcomes.

As children with severely reduced kidney function are primarily managed by paediatric nephrology teams, this cohort is expected to be broadly representative. There are however limitations. This group represents children with CKD known to specialist care. A population-level Turkish study of children aged 5–18 years reported a prevalence of severely reduced eGFR (<30 mL/min/1.73 m2) of 0.06%7; applying these estimates to the UK cohort would mean up to 6600 children are affected. Exclusion of patients with insufficient data to discern CKD stage may result in underestimation of the true prevalence of stage 4 and 5 (non-KRT) CKD. Due to incomplete capture of young people in both adult and paediatric settings, estimates for those aged 16–18 years were imprecise and therefore excluded from analysis.

Expansion of the data held by the UKRR and linkages to other health datasets (such as NHS Digital) provides an opportunity to describe the epidemiology and outcomes of this cohort. Moreover, a planned merger of the UKRR paediatric and adult datasets will enable longitudinal appraisal of disease. With increasing public concern over the misuse of patient data, it is important to highlight the thorough governance processes the UKRR maintains to securely hold and analyse patient-level data, as described below.

There is increasing evidence that factors early in life confer a risk of subsequent kidney disease and failure.8 It is therefore imperative that we, as paediatricians, can identify children with kidney disease that may benefit from earlier intervention. This would enable access to treatments that support optimal growth and development, delay progression to failure and allow timely consideration of transplantation. This must be supported by robust data collection, to monitor disease progression and identify factors and interventions that confer health and economic benefits, in childhood and beyond. This UKRR-BAPN initiative has shown we can rise to this challenge, which will support healthcare planning for all ages.

Ethics statements

Patient consent for publication

Ethics approval

The UK Renal Registry has a legal basis to collect and analyse data under section 251 support for audit and research in England and Wales. Data from Scotland are provided by the Scottish Renal Registry, and Northern Ireland by Department of Health and Social Care for Northern Ireland.



  • Twitter @ledicmucy

  • Contributors LP, SM, CI, DN and JM designed and coordinated the data collection process in response to COVID-19 infection concerns for children with kidney disease; CI, MC, S Haq, S Hegde, AL, MM, HM, MM, SM, BR, MDS, KT and DW collated centre data; WM and AC analysed data; LP drafted and revised the manuscript with intellectual input from the authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests LP declares funding from the National Institute for Health Research (NIHR) and Kidney Research UK (KRUK). BCR declares funding from KRUK, honoraria from Alexion Pharmaceuticals and Magnolia Innovation, and consultancy payment from Chiesi. MM reports previous honoraria and travel expenses from Alexion. SM declares a role as head of the UK Renal Registry Audit and Informatics group. KT declares a role as clinical lead of the National Institute for Health and Care Excellence Medical Technologies Advisory Committee during the study period. DN declares funding/payment from the Health Foundation, UK Kidney Association, Chiang Mai University and GSK.

  • Provenance and peer review Not commissioned; externally peer reviewed.